Fluoroquinolones: Difference between revisions
(Created page with "==Fluoroquinolones== * UTI (2nd line) * Prostatitis * Chlamydia * PID * Traveler's diarrhea {{Template:Clinically Utilized Antibiotics}} ==See Also== *Antibiotics (Mai...") |
No edit summary |
||
| (10 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
== | ==Indications== | ||
* UTI (2nd line) | *[[UTI]] (2nd line) | ||
* Prostatitis | *[[Prostatitis]] | ||
* Chlamydia | *[[Chlamydia]] | ||
* PID | *[[PID]] | ||
* Traveler's | *[[Traveler's Diarrhea]] | ||
==Adverse Effects== | |||
*Common adverse effects | |||
**GI and neuro toxicity | |||
**Rash | |||
**QT prolongation | |||
**Hyper/hypoglycemia | |||
**Hematologic toxicity | |||
**Depression/Suicidality | |||
*Black box warning from US FDA | |||
**Tendonitis and tendon rupture<ref>Gültuna S. et al. Ciprofloxacin induced tendinitis. J Clin Rheumatol. 2009;15 (4): 201-2</ref> | |||
**Peripheral Neuropathy<ref>Food and Drug Administration: Drug safety announcement about fluoroquinolones and possible peripheral neuropathy [http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf PDF]</ref> | |||
{{Template:Clinically Utilized Antibiotics}} | {{Template:Clinically Utilized Antibiotics}} | ||
| Line 11: | Line 23: | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
== | ==External Links== | ||
*[http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm126085.htm FDA info for Health Professionals] | |||
==References== | |||
<references/> | |||
[[Category:ID]] | [[Category:ID]] | ||
[[Category: | [[Category:Pharmacology]] | ||
Latest revision as of 00:02, 16 November 2018
Indications
- UTI (2nd line)
- Prostatitis
- Chlamydia
- PID
- Traveler's Diarrhea
Adverse Effects
- Common adverse effects
- GI and neuro toxicity
- Rash
- QT prolongation
- Hyper/hypoglycemia
- Hematologic toxicity
- Depression/Suicidality
- Black box warning from US FDA
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||